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Abstract
There is currently no absolute immunohistochemical positive marker for the definite 
diagnosis of malignant mesothelioma. Therefore, the aim of this study was to identify novel positive 
markers of malignant mesothelioma. Whole genome gene expression analysis was performed using 
RNA extracted from formalin-fixed paraffin-embedded tissue sections of epithelioid mesothelioma 
(EM) and lung adenocarcinoma (LAC). Gene expression analysis revealed that disabled homolog 2
(DAB2) and Intelectin-1 had significantly higher expression in EM compared to that in LAC. The 
increased mRNA expression of DAB2 and Intelectin-1 was validated by RT-PCR of RNA from 
tumor tissue and protein expression was validated by western blotting of five mesothelioma cell lines.
The utility of DAB2 and Intelectin-1 in the differential diagnosis of EM and LAC was examined by 
an immunohistochemical study of 75 cases of epithelioid mesothelioma and 67 cases of lung 
adenocarcinoma. The positive rates of DAB2 and Intelectin-1 expression in EM were 80.0% and 
76.0%, respectively, and 3.0% and 0%, respectively, in LAC. Immunohistochemically, the 
sensitivity and specificity of DAB2 was 80% and 97% and those of Intelectin-1 were 76% and 100% 
for differentiation of EM from LAC. In conclusion, DAB2 and Intelectin-1 are newly identified 
positive markers of mesothelioma and have potential to be included in future immunohistochemical 
marker panels for differentiation of EM from LAC.
Key words
DAB2, Intelectin-1, gene expression analysis, immunohistochemistry, epithelioid mesothelioma, 
lung adenocarcinoma
  4 
Introduction 
Malignant mesothelioma is a rare and fatal malignant tumor (1). In Japan, the mesothelioma 
death rate is increasing, approaching 1500 deaths in 2015, increased from 500 in 1995 according to 
Vital Statistics data published by the Ministry of Health, Labour and Welfare, Japan (2). Similarly, 
the death rate due to mesothelioma is increasing globally, including the UK and Ireland (3), USA 
and other developing countries (4). Asbestos exposure is the main risk factor for malignant pleural 
mesothelioma, including both occupational and environmental exposure. The time interval between 
first exposure to asbestos and diagnosis of mesothelioma is speculated to range from 20 to 50 years.
Apart from the relatively long time it takes for asbestos to cause disease, delayed onset of symptoms
can contribute to late-stage diagnosis and by then, the cancer spreads into the thoracic cavity and is 
more difficult to treat. Therefore, accurate diagnosis of mesothelioma is essential for its correct 
management.
A common site of origin of malignant mesothelioma is the pleura followed by other tissues 
including the peritoneum, pericardium and tunica vaginalis. Malignant mesothelioma is classified 
into three major histological subtypes: epithelioid, sarcomatoid, and biphasic as described in the 
2015 World Health Organization (WHO) KLVWRORJLFDOFODVVL¿FDWLRQRIWXPRUVRIOXQJDQGSOHXUD
2015 (5). Epithelioid mesothelioma (EM), which constitutes more than 60% of all mesothelioma, is 
the most common histological subtype, and has a relatively better prognosis than sarcomatoid or 
biphasic mesothelioma. EM shows various histological patterns including tubulopapillary, 
micropapillary, acinar, adenomatoid, and solid. As EM closely resembles other malignant tumors 
showing pseudomesotheliomatous growth patterns, such as those of primarily lung carcinoma, breast 
carcinoma, and cancer that affects the lining of internal organs, the diagnosis of malignant 
mesothelioma is challenging, both histopathologically and clinically. Currently, the final diagnosis of 
malignant mesothelioma requires thorough reviewing of clinico-radiological and pathological 
findings (gross examination and histological findings in tissue samples) with adequate 
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immunohistochemical and/or genetic analyses. As an immunohistochemical marker with absolute 
sensitivity and specificity is not yet available, the search for additional novel immunohistochemical 
markers is critical.
The aim of this study was to identify novel positive immunohistochemical markers by 
analysis of whole gene expression data using microarray gene chips. We performed gene expression 
analysis on epithelioid cells dissected from formalin-fixed paraffin-embedded (FFPE) tissue of EM 
and lung adenocarcinoma (LAC) and identified several novel genes that are differentially expressed 
between EM and LAC. Of these, we identified disabled homolog 2 (DAB2) and Intelectin-1 as 
potential novel positive immunohistochemical markers of EM for differentiation from LAC.
Materials and methods
Patients and histological samples
The materials included in this study were obtained from the archives of the Department of 
Pathology, Hiroshima University. The study group consisted of 75 patients with Epithelioid 
mesothelioma (EM) who had undergone thoracoscopic pleural biopsy, pleurectomy/decortication, 
extrapleural pneumonectomy, or autopsy between 2000 and 2016. Between 2005 and 2016, 67 lung 
adenocarcinoma (LAC) cases were also obtained via thoracoscopic surgical segmentectomy or 
lobectomy of lung harboring adenocarcinoma$OOPLFURVFRSLFVOLGHVZHUHUHYLHZHGDQGUHFODVVL¿HG
XVLQJWKHFXUUHQW:+2KLVWRORJLFDOFODVVL¿FDWLRQRIWXPRUVRIOXQJDQGSOHXUD (6) by four 
pathologists (MK, KK, VJA, and YT). Pathological diagnosis of each case was confirmed by 
histological findings and an immunohistochemical marker panel recommended by Guidelines for 
Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from 
the International Mesothelioma Interest Group (IMIG) (7) and current 2015 WHO histological 
classification of tumors of the lung, pleura, thymus and heart (6).
Anonymized tissue samples were provided by the Department of Pathology for gene 
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expression and immunohistochemical analysis. This study was carried out in accordance with the 
Ethics Guidelines for Human Genome/Gene Research enacted by the Japanese Government for the 
collection of tissue specimens and was approved by the institutional ethics review committee
(Hiroshima University E-974).
Gene expression analysis
Identification of genes with marked difference between epithelioid mesothelioma and lung 
adenocarcinoma
Formalin-fixed paraffin-embedded sections from six EM cases and six LAC cases were used 
for gene expression analysis. RNA extraction for gene expression analysis was performed from 
papillary or solid growth of tumor cells in each specimen. Five 10 ȝm thick FFPE tumor tissue 
sections, each approximately 1 cm in diameter, were processed for total RNA extraction using the 
Maxwell RSC RNA FFPE Kit (Promega KK, Tokyo, Japan) according to the manufacturer’s 
protocol. Briefly, after deparaffinization and lysis with proteinase K, the samples were treated with 
DNase I for 15 min at room temperature. Following this, RNA purification was carried out according 
to the manufacturer’s protocol using a Maxwell RSC automation instrument (Promega). RNA quality 
check and quantification was performed as described previously (8) and RNA with an absorbance 
ratio RI between 260 nm and 280 nm was used for microarray analysis. The Human 
Transcriptome 2.0 GeneChip Array (Affymetrix, Santa Clara, CA, USA) containing gene transcript 
sets of 44,699 protein coding and 22,829 non-protein coding clusters was used to analyze gene 
expression profiles. Total RNA was amplified and labeled with a 3ƍ IVT Labeling Kit (Affymetrix) 
before hybridization onto the GeneChip. Briefly, 100 ng total RNA was amplified with GeneChip 3ƍ
IVT Pico kit (Affymetrix) to generate 30 ȝg of SenseRNA according to the manufacturer’s protocol. 
SenseRNA ȝg) was labeled with a 3ƍ IVT Labeling Kit (Affymetrix) and hybridized to a Human 
Transcriptome 2.0 GeneChip (Affymetrix) as described previously (8). The data were analyzed using 
the Gene Expression Console Software (Affymetrix), and further statistical analyses were performed 
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using the Subio Software Platform (Subio, Amami-shi, Japan) to plot graphs and for fold change of 
expression and hierarchical clustering.
Validation of gene expression analysis
Real-time reverse transcriptase polymerase chain reaction
The same six cases of EM and LAC that were analyzed for gene expression profiling were 
used to validate the microarray expression data by mRNA expression. The relative mRNA 
expression of DAB2 and Intelectin-1 was assessed with SYBR Green-based real-time RT-PCR using 
GAPDH as a control. A total of 100 ng of RNA was used for mRNA expression with a VeryQuest 
SYBR Green one-step RT-PCR Master Mix (Affymetrix) using a Stratagene Mx3000P qPCR 
System (Agilent Technologies, Santa Clara, CA, USA). The primer pairs used for amplification of 
DAB2 and Intelectin-1 were DAB2-F: GTA GAA ACA AGT GCA ACC AAT GG, DAB2-R: GCC 
TTT GAA CCT TGC TAA GAG A, ITLN1-F: ACG TGC CCA ATA AGT CCC C, ITLN1-R: CCG 
TTG TCA GTC CAA CAC TTT C. Primers for GAPDH were GAPDH-F: ACA ACT TTG GTA 
TCG TGG AAG G, GAPDH-R: GCC ATC ACG CCA CAG TTT C. Data analysis was performed 
XVLQJWKHįį&7PHWKRGIRUUHODWLYHTXDQWLILFDWLRQ%ULHIO\WKUHVKROGF\FOHV&7IRU*$3'+
(control) and DAB2 and Intelectin-1 (samples) were determined in triplicate. The relative expression 
(rI) was calculated using the formula: rI = 2- (CT sample - CT normal).
Western blotting
Total proteins were extracted from five commercially available mesothelioma cell lines
(ACC-MESO-1, CRL-5915, ACC-MESO-4, CRL-5946, HMMME) using cell lysis protein 
extraction reagent (Cell-LyEX1 kit, TOYO B-Net, Tokyo, Japan). Approximately 25 ȝJ of protein 
was subjected to electrophoresis on a Novex 10% Bis-Tris gel using a Bolt mini gel tank (Thermo 
Fisher Scientific, Yokohama, Japan). The proteins were then transferred to a Hybond-P PVDF 
membrane (GE Healthcare, Buckinghamshire, UK) using a Mini Blot Module (Thermo Fisher 
Scientific). After treating with blocking buffer, the transfer membrane was incubated with anti-
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DAB2 antibody (1:2000 rabbit polyclonal, catalog #HPA028888, Sigma-Aldrich, St. Louis, MO, 
USA), anti-Human Intelectin-1 (mouse monoclonal 3G9, Immuno-Biological Laboratories, Gunma, 
Japan, 1:2000) overnight at 4°C. This was followed by streptavidin-labeled anti-mouse or anti-rabbit 
secondary antibodies (Cell Signaling Technology, Tokyo, Japan) and Immunostar LD (Wako Pure 
Chemicals, Tokyo, Japan) as a chemiluminescent detection reagent. Anti-GAPDH antibody (rabbit 
polyclonal, Santa Cruz Biotechnology, CA, USA) was used as control. The blot membrane was 
captured by scanning with C-DiGit Blot Scanner (LI-COR) for detection of proteins of interest.
Immunohistochemical procedures and evaluation of expression of DAB2 and Intelectin-1
Immunohistochemistry was performed using 3 ȝPWLVVXHVHFWLRQVSUHSDUHGIURPWKHEHVW
representative FFPE blocks of EM and LAC cases. Immunohistochemical staining was performed 
using the Ventana Benchmark GX automated immunohistochemical station (Roche Diagnostics, 
Tokyo, Japan). Cell Condition buffer #1 at 95°C for 32 min (Roche Diagnostics) was used for antigen 
retrieval. The sections were then incubated with primary antibodies to calretinin (rabbit monoclonal, 
SP65, prediluted, Roche Diagnostics), podoplanin (mouse monoclonal, D2-40, Prediluted; Nichirei
Bioscience, Tokyo, Japan), Wilms’ tumor gene product (WT1) (mouse monoclonal, 6F-H12, 1:25; 
Dako, Glostrup, Denmark), DAB2 (rabbit polyclonal, catalog #HPA028888, 1:200; Sigma-Aldrich),
and Intelectin-1 (mouse monoclonal, 3G9, 1:1000; Immuno-Biological Laboratories). Incubation 
with the secondary antibody and detection was performed with Ventana ultraView Universal DAB 
Detection Kit.
Immunoreactivity was scored as either negative (no immunostaining) or positive. Cells 
showing nuclear staining for calretinin and WT1, cytoplasmic staining for DAB2 and Intelectin-1, or 
membranous staining for podoplanin (clone: D2-40) were recorded as ‘positive’. Positive 
immunoreactivity was further scored as 1+ for up to 10% of tumor cells showing positive 
immunostaining, 2+ for 10–50% positive tumor cells, and 3+ for more than 50% positive tumor cells. 
Statistical analyses were performed using Fisher’s exact test. Sensitivity, specificity, positive 
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predictive value, negative predictive value, and accuracy rate were calculated using a simple 2 × 2 
table.
Results
Differential gene expression and validation in epithelioid mesothelioma and lung adenocarcinoma 
Out of the 44,699 protein coding and 22,829 non-protein coding transcripts on the Human 
Transcriptome 2.0 GeneChip Array, 902 statistically significant mRNA transcripts were 
differentially expressed, with a greater than 1.3-fold difference, between EM and LAC (Figure 1). 
Hierarchical clustering of 426 protein coding mRNA transcripts revealed 197 upregulated mRNA 
transcripts in EM, including CALB2, WT1, DAB2, and Intelectin-1, and 229 upregulated mRNA 
transcripts in LAC, including CEACAM6 and NAPSA (Figure 2; Supplementary Table S1). 
Real-time RT-PCR showed relative mRNA expression of DAB2 and Intelectin-1 was 
significantly higher in EM than that in LAC (data not shown). Western blot analysis showed DAB2 
and Intelectin-1 protein expression in all five commercially available mesothelioma cells lines with
an electrophoretic band of 80 kDa with DAB2 and one or two electrophoretic bands in the range of 
30–40 kDa with the Intelectin-1 antibody (Figure 3).
Immunohistochemical expression profiles in epithelioid mesothelioma and lung adenocarcinoma
The expression of positive mesothelioma markers are summarized in Table 1 and the 
representative images for DAB2 and Intelectin-1 expression in EM and LAC are presented in Figure 
4 and Figure 5 respectively. The staining pattern for each marker in two tumor types is described in 
the following sections.
DAB2 and Intelectin-1 expression
The expression of DAB2 and Intelectin-1 was localized in the cytoplasm of tumor cells in EM
cases. Positive DAB2 expression was observed in 60 of 75 EMs (80.0%) and 2 of 67 LACs (3.0%). 
In half of EM cases, DAB2 immunoreactivity was generally strong and diffuse (score 3+). In 
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contrast, LACs showing DAB2 expression was focal (score 1+). In addition, DAB2 expression in 
alveolar macrophages in LACs was a helpful internal positive control. Positive Intelectin-1
expression was observed in 57 of 75 EMs (76.0%), with most of them showing score 3+, whereas 
none of the 67 LACs were positive for Intelectin-1.
Calretinin, D2-40, and WT1 expression
Positive calretinin expression was recorded for 74 of 75 EMs (98.7%) and 17 of 67 LACs 
(25.4%). In EMs, immunoreactivity was generally strong and diffuse (score 3+). In contrast, staining 
score in LACs was 1+ and 2+. There were no score 3+ cases in LACs. Positive D2-40 expression 
was observed in 71 of 75 EMs (94.7%), with most of them showing score 3+, whereas only seven 
LACs (10.4%) were focally positive (score 1+ and 2+) for D2-40. Positive WT1 expression was 
recorded in 62 of 75 EMs (82.7%), whereas none of 67 LACs (0%) were positive for WT1.
Sensitivity and specificity of each marker for differential diagnosis of epithelioid mesothelioma 
and lung adenocarcinoma
The sensitivity and specificity of each marker for the differential diagnosis between EM and 
LAC are shown in Table 2. Sensitivity of Intelectin-1 (76%) was lowest amongst five positive 
markers; however, its specificity (100%) was absolute. Sensitivity (80.0%) and specificity (97.0%) 
of DAB2 were nearly those of WT1. Specificity of calretinin (74.6%) was lowest amongst five 
markers.
Discussion
Pathologically, the role of immunohistochemistry in distinguishing pleural EM from LAC 
has received much attention especially in the last 20 years. Currently, there are many 
immunohistochemical markers available for distinguishing EM from LAC. Among these, calretinin, 
cytokeratin 5/6, podoplanin (D2-40), and WT1 are the preferred positive markers for EM.
Carcinoembryonic antigen (CEA), MOC31 [epithelial-related antigen (ERA)], Ber-EP4, BG-8,
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thyroid transcription factor-1 (TTF-1), claudin-4, and napsin-A are the preferred positive markers for 
LAC. The IMIG 2012 guidelines recommended the consideration of two mesothelial and two 
carcinoma markers, based on morphology at initial observation (7). In practice,
immunohistochemical examination, most laboratories use calretinin, D2-40, and WT1 for diagnosis 
of EM. However, pathologists must interpret the results of staining by these markers carefully, as
specificity of calretinin (74.6% in this study, 90-95% in IMIG 2012 guidelines) and D2-40 (88.9% in 
this study, up to 85% in IMIG 2012 guidelines) is not absolute; additionally, WT1 shows low 
sensitivity (82.7% in this study, approximately 90–100% in IMIG 2012 guidelines). Therefore, novel 
positive immunohistochemical markers, other than calretinin, D2-40, or WT1, are necessary for 
increasing the accuracy of EM diagnosis.
Recent development of molecular techniques enabled gene expression analysis from RNA 
extracted from archival FFPE tumor tissues using GeneChip technology. This method is very useful 
to find new diagnostic markers, especially in rare tumors, including malignant mesothelioma. We 
have recently reported the identification of a novel marker, MUC4, for differentiating pleural 
sarcomatoid mesothelioma from lung sarcomatoid carcinoma by analyzing gene expression data 
from a gene chip microarray (8). In this study, we performed gene expression microarray analysis to 
identify differentially expressed gene products in EM and LAC. We found that the expression of 
DAB2 and Intelectin-1 in EM was significantly higher than that in LAC and this was validated by 
real-time RT-PCR analysis of mRNA extracted from the same tissue source and western blot analysis 
of proteins extracted from mesothelioma cell lines. Immunohistochemical analysis showed that
expression of DAB2 and Intelectin-1 in EMs was significantly higher than that in LACs. These novel 
positive mesothelial markers, DAB2 and/or Intelectin-1, contribute in accurate mesothelioma 
diagnosis, in addition to known positive markers (calretinin, D2-40, and WT1). 
DAB2, a mitogen-responsive phosphoprotein, is expressed in normal ovarian epithelial cells, 
but is down-regulated or absent from ovarian carcinoma cell lines, suggesting its role as a tumor 
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suppressor (9). Decreased DAB2 expression has been reported in various human cancers, including 
esophageal (10), lung (11), ovarian (9), prostate (12), and breast (13) cancers. DAB2 downregulation 
in these cancers were reported partly due to miRNA targeting DAB2 (10, 14) or promoter 
hypermethylation (13, 15). However, the biological significance or expression of DAB2 has not yet 
been reported in malignant mesothelioma. In the present study, we found increased expression of 
DAB2 in EM compared to that in LAC by gene expression microarray analysis. We also confirmed 
this increased expression of DAB2 in EM by real-time RT-PCR and western blot. From the 
differential analysis of DAB2 expression between EM and LAC by immunohistochemical study, we 
found higher sensitivity and specificity in EM of more than 80%. In two of the 67 cases of LAC, 
DAB2 expression was identified in tumor cells but with a low immunoreactivity score. DAB2 
expression in LACs was present in inflammatory cell infiltration, mainly macrophages; therefore,
precaution must be taken by the physician when interpreting LAC results for DAB2 expression.
Human Intelectin-1, also known as omentin, is a galactose-binding lectin that is usually 
expressed in the heart and small intestine as a host defense lectin that binds to bacterial 
galactofuranose (16). Intelectin-1 is mainly expressed in the intestinal goblet cells and omentum, and 
occasionally in the thymus, bronchus, heart, liver, kidney collecting tubule cells, bladder umbrella 
and mesothelial cells (17). Recently, the overexpression of Intelectin-1 in human malignant pleural 
mesothelioma and its secretion into pleural effusions indicated towards it being a potential biomarker 
(17, 18). It was reported that Intelectin-1 was not expressed in various cancers, except in some 
mucus-producing adenocarcinomas (19). In the present study, we observed high expression of 
Intelectin-1 mRNA in EM, definite expression of Intelectin-1 in mesothelioma cell lines by western 
blot analysis, and in 57 of 75 mesothelioma tissue samples by immunohistochemical analysis. 
Additionally, we also found Intelectin-1 expression in non-neoplastic mesothelial lining cells and 
goblet cells in bronchi and bronchioles (data not shown). No Intelectin-1 expression was recorded in 
any LAC cases, confirming its potential as a novel positive mesothelial marker. The functional roles 
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of DAB2 and Intelectin-1 expression in EM need further analysis, which is beyond the scope of this 
study.
In conclusion, we identified two novel positive markers of EM, DAB2 and Intelectin-1, by 
using gene expression microarray analysis and confirmed their utility to differentiate EM from LAC 
by immunohistochemical study. Further validation of immunohistochemical staining of these 
markers by other institutes is warranted.   
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Figure Legends
Figure 1. Scatter plot diagram showing differential expression of various genes between epithelioid 
mesothelioma and lung adenocarcinoma. Note, DAB2 and Intelectin-1 locate towards the epithelioid 
mesothelioma, in addition to previously known mesothelioma positive markers, CALB2 (calretinin) 
and WT1, while NAPSA (Napsin-A) and CEACAM6 (major gene for CEA), positive lung 
adenocarcinoma markers, locate towards lung adenocarcinoma.
Figure 2. Supervised hierarchical clustering of differentially expressed genes between epithelioid 
mesothelioma and lung adenocarcinoma. The hierarchical clustering of 426 protein coding mRNA 
transcripts revealed 197 upregulated mRNA transcripts in EM and 229 upregulated mRNA 
transcripts in LAC. See detailed data in Supplementary Table S1.
Figure 3. Western blot showing DAB2 and Intelectin-1 expression in mesothelioma cell lines. DAB2 
expression is present in all five mesothelioma cell lines as a single band; however, Intelectin-1
expression is present as either a single or double band.
Figure 4. DAB2 and Intelectin-1 expression in epithelioid mesothelioma.
Various histomorphological patterns of epithelioid mesothelioma showing prominent expression of 
DAB2 (middle column) and Intelectin-1 (right column). Each row shows epithelioid mesothelioma 
with corresponding DAB2 and Intelectin-1 immunohistochemistry.
Figure 5. DAB2 and Intelectin-1 expression in lung adenocarcinoma.
Various histomorphological patterns of lung adenocarcinoma showing no expression of DAB2 
(middle column) and Intelectin-1 (right column). Each row shows lung adenocarcinoma with 
corresponding DAB2 and Intelectin-1 immunohistochemistry. There is focal reactivity of DAB2 in 
alveolar macrophages and lymphocytes, which need to interpreted with care.
